Health Care

Analyst Review: Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)

0 17

Shares of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) climbed +3.33% and ended at $2.79 greater than previous closing price of $2.70. The total 1 million shares were bought and sold throughout the most recent trading session more than average volume of 580.49 thousand shares.

Currently Idera Pharmaceuticals, Inc. (IDRA) captured an average recommendation of “ Buy ” from analysts, according to FactSet data. The stock has been suggested as “Buy” from “3″ Analysts”. “0” rated “Sell” for the company. “0” said the company as a “Hold”. Overweight rating was given by “0” and Underweight rating was given by “0”.

Analysts are expecting that the company to achieve $5.00 Price Target in next 52-weeks, average price is come up through the consensus of analysts. High potential price target is set at $6.00 however minimum price target advised by analysts is $4.00. The Median price target for the stock is measured at $5.00.

Presently, Analysts decided consensus EPS estimate of $-0.11 for present quarter and one month ago projected EPS estimate was at $-0.11. If we take a look at back 3 month ago, consensus EPS estimate was $-0.12.

A current consensus EPS estimate for next quarter is at $-0.11 and 3 month ago EPS forecast was $-0.11. Have a look at back 1 month ago, consensus EPS forecast was seen at $-0.11.

For current fiscal year, most recent EPS estimate is set at $-0.45 based on Analyst consensus and three month ago consensus EPS opinions was at $-0.44. During period one month ago, consensus EPS forecast was decided at $-0.45.

A current consensus EPS projection for next fiscal year is observed at $-0.46 and one month ago consensus EPS forecast was at $-0.46. Take a look at back three month ago, consensus EPS estimate opinions was decided at $-0.46 by analysts.

One Month ago, the stock has gained consensus mean rating of Buy based on the analysis of brokerage analyst firms polled. 3 presented the recommendations about the stock as a “Buy” signal and “Overweight” signal was reported by 0. 0 advised the “Hold” rating about this stock. 0 revealed “Sell” signal and “Underweight” rating was declared by 0.

Three Months Ago, Analysts recommended an average brokerage rating of Buy derived from brokerage firms, according to FactSet. 4 said a “Buy Rating” and 0 announced “Overweight Rating”. 0 advised “Hold Rating” regarding the stock. 0 announced “Sell Rating” and 0 disclosed “Underweight Rating”.

About the author / 

Leave a reply

Your email address will not be published. Required fields are marked *

About Us

WSnews4investors is the influential source for financial news and Opinion Company with content which delivered over the Internet. WSnews4investors is a dynamic and innovative financial media outlet that empowers investors with high-quality, unique content that is coveted by Wall Street’s traders.

Newsletter